Gemin X Pharmaceuticals (Malvern, PA) a clinical-stage biopharmaceutical company focused on chronic lymphocytic leukemia, melanoma, small cell lung cancer, lymphoma, myeloma and glioblastoma multiforme, closed a $8M Series E financing. Participants include Caxton Advantage Life Sciences Fund and Sanderling Ventures.

Calistoga Pharmaceuticals (Seattle, WA) a clinical-stage small molecule company focused on isoform-selective phosphatidylinositol 3 kinase inhibitors for the treatment of cancer and inflammatory diseases, closed a $40M Series C financing. Participants include Quogue Capital, Alta Partners, Amgen Ventures, Frazier Healthcare, Three Arch Partners and Latterell Venture Partners.

Metamark Genetics (Cambridge, MA) a development-stage molecular diagnostics company focused on prognostic assays for early-stage cancers, closed a $22M Series B financing. Participants may have included Perseus.

Calithera Biosciences (San Francisco, CA) a preclinical-stage small molecule company focused on caspase activators for oncologic applications, closed a $40M Series A financing. Participants include Morgenthaler Ventures, U.S. Venture Partners, Advanced Technology Ventures, Delphi Ventures and Mission Bay Capital.

Mirina (Seattle, WA) a development-stage biotechnology company focused on miRNA therapeutics for oncology and metabolic disorders, closed a $3.9M Series A financing, bringing the total round to $7.5M. Participants include Versant Ventures, Alexandria Real Estate Equities, ARCH Venture Partners, OVP Venture Partners and WRF Capital.

TPP Global Development (United Kingdom) a preclinical-stage drug development company focused on acquiring and developing early-stage intellectual property in the CNS, inflammation and oncology sectors, closed a $12.2M Series A financing. Participants include Scottish Venture Fund.

Coronado Biosciences (Seattle, WA) a clinical-stage biopharmaceutical oncology company focused on AML, NSCLC, leukemia, lymphoma, and prostate cancer. Participants were not identified.

Bind Biosciences (Cambridge, MA) a preclinical-stage nanoparticle platform company focused on increased efficacy and reduced toxicity of currently marketed drugs, closed a $12.4M Series C financing. Participants include Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension, DHK Investments and Endeavour Vision.

Nereus Pharmaceuticals (San Diego, CA) a clinical-stage small molecule company focused on non-small cell lung cancer and myeloma, closed a $20M Series E financing. Participants include HBM BioVentures, Alta Partners, Forward Ventures, Gimv, Advent International, Pacific Venture Group, Roche Venture Fund and Astellas Venture Management.

Aquinox Pharmaceuticals (Canada) a preclinical-stage small-molecule drug company focused on cancer, immune disorders and metabolic disease, closed a $25M Series B financing. Participants include Ventures West Capital, Johnson & Johnson Development Corp., Baker Brothers Investments, BC Advantage Funds and Pfizer Venture Investments.